20500 ā
Medicinal preparations containing organic active ingredients; Phosphorus compounds; Phosphorus acids or esters thereof having PāC bonds, e.g. foscarnet, trichlorfon Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
#302Methods to modulate Rac1 import and to treat pulmonary fibrosis
#303Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
#304DENTAL IMPLANT HAVING ENHANCED EARLY STABILITY AND METHOD FOR MANUFACTURING SAME
#305Enteric soft capsules
#306Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
#307Treatment and prevention of bone loss using resolvins
#308Composition of dialysis liquid comprising crystallisation inhibitor substances
#309Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
#310Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
#311METHODS AND COMPOUNDS FOR CALCIUM ION CHANNEL REGULATION
#312PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM
#313Transmucosal drug delivery system
#314Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
#315METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES
#316M-CSF specific monoclonal antibody and uses thereof
#317Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient
#318Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
#319Solid Dosage Form
#320Treatment and prevention of dental pathology in humans and non-human animals
#321Methods of promoting fat loss comprising administering an ALK7 inhibitor
#322Cell-free tissue engineered vascular grafts
#323MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY
#324LLP2A-bisphosphonate conjugates for osteoporosis treatment
#325Bone targeted therapeutics and methods of making and using the same
#326METHODS OF TREATING SUBCHONDRAL BONE TO PREVENT THE PROGRESSION OF OSTEOARTHRITIS IN JOINTS
#327SELECTIVE ANDROGEN RECEPTOR MODULATORS
#328Treatment and prevention of cardiovascular disease and thrombosis
#329Biologically active supplements and process of its production
#330METHOD FOR INDUCING FAT LOSS IN MAMMALS
#331Patch and patch preparation
#332Patch and patch preparation
#333Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
#334Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins
#335Phosphaplatins and their use in pharmaceutical compositions
#336Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
#337COMBINATION THERAPIES FOR TREATING NEUROLOGICAL DISORDERS
#338Composition for preventing or treating osteoporosis, and manufacturing method therefor
#339METHODS AND COMPOSITIONS FOR INHIBITION OF BETA2-ADRENERGIC RECEPTOR DEGRADATION
#340Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
#341COMPOSITIONS FOR DENTAL TREATMENT COMPRISING LIPOTEICHOIC ACIDS OR PARTS THEREOF LIKE MONO- OR POLYGLYCERPHOSPHATES
#342PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATE WITH ENHANCED ORAL BIOAVAILABILITY
#343Dosage forms of bisphosphonates
#344Polynucleotides encoding antibodies against sclerostin and uses therefor
#345Antibody targeting osteoclast-related protein Siglec-15
#346Treatment and prevention of dental pathology in humans and non-human animals
#347Antibody targeting osteoclast-related protein siglec-15
#348Methods for treating heart failure using bisphosphonate compositions
#349Synergistic antimicrobial composition
#350Enzyme inhibiting compounds and methods
#351FORMULATIONS AND METHODS FOR RECOVERY FROM DENTAL SURGERY
#352COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME
#353Methods of promoting fat loss comprising administering an ALK7 inhibitor
#354Bisphosphonates as Inhibitors of Acid Sphingomyelinase
#355Methods useful in the treatment of bone resorption diseases
#356Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
#357NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
#358Aqueous drug delivery system
#359Molecular tweezers for the treatment of amyloid-related diseases
#360KINASE PROTEIN BINDING INHIBITORS
#361TARGETED LIPOSOMES COMPRISING N-CONTAINING BISPHOSPHONATES AND USES THEREOF
#362Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
#363DOSAGE FORMS OF RISEDRONATE
#364Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses, Or Conditions
#365Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases
#366Bone Modulators And Methods Therewith
#367Methods of treating aneurysm
#368Bisphosphonate Formulation
#369Phosphate management with small molecules
#370Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
#371TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES
#372SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME
#373Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
#374Pharmaceutical composition for the prevention and treatment of bone tissue resorption of various etiology
#375CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE
#376MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY
#377Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage
#378OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT
#379METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
#380Activation of the Renin-Angiotensin System (RAS) and Sudden Cardiac Death
#381Effervescent compositions comprising phosphonates and methods related thereto
#382Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
#383METHODS OF TREATING AND PREVENTING NEUROLOGICAL DISORDERS USING DOCOSAHEXAENOIC ACID
#384Composition of dialysis liquid comprising crystallisation inhibitor substances
#385Functional Micelles for Hard Tissue Targeted Delivery of Chemicals
#386COSMETIC AND/OR DERMATOLOGICAL COMPOSITION
#387Methods For Preserving Ophthalmic Solutions and Preserved Ophthalmic Solutions
#388COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR
#389THERAPY OPTION FOR RECOLORATION OF HAIR VIA BISPHOSPHONATES BY PHYSIOLOGICAL REPIGMENTATION WITH AGE-RELATED AND/OR PREMATURE "GRAYED" PATIENTS
#390INHIBITION OF POST-RADIATION TUMOR GROWTH
#391Methods useful in the treatment of bone resorption diseases
#392ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF
#393CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE
#394Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
#395Compositions and methods for use for antibodies against sclerostin
#396PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE
#397Formulations and methods of using nitric oxide mimetics in cancer treatment
#398Pharmaceutical and cosmetic compositions including lactoferrin, ciclopirox, etidronic acid
#399Formulation and Method for the Prevention and Treatment of Bone Metastases or Other Bone Diseases
#400ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF
#401METHODS OF REDUCING THE SEVERITY OF MUCOSITIS
#402Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
#403TRANSDERMALLY ABSORPTIVE PREPARATION
#404Method and Means for the Treatment of Cachexia
#405Solid oral dosage form containing an enhancer
#406Prenylated Bisphosphonates as Anti-tuberculosis Agents
#407COMPOSITIONS COMPRISING UNSATURATED FATTY ACIDS AND NITRIC OXIDE RELEASING COMPOUNDS AND USE THEREOF FOR ENHANCING COGNITIVE AND RELATED FUNCTIONS
#408Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
#409Energy absorbing thermoplastic elastomer
#410METHODS COMPOSITIONS AND ARTICLE OF MANUFACTURE FOR MODULATING BONE GROWTH
#411Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
#412PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY ABNORMAL BONE METABOLISM
#413Antibody targeting osteoclast-related protein Siglec-15
#414Method of Treatment Using Bisphosphonic Acid
#415Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
#416NANOPARTICLE COMPOSITIONS
#417FORMULATIONS COMPRISING VITAMIN D OR DERIVATIVES THEREOF
#418Treatment of arthritis with parathyroid hormone
#419NORTRIPTYLINE COMPOUNDS FOR PROMOTING BONE GROWTH
#420PHARMACEUTICAL COMPOSITION COMPRISING A HOT-MELT GRANULATED LUBRICANT
#421HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatment of conditions related to prenylated proteins in cells
#422DOSAGE FORMS OF RISEDRONATE
#423Low dosage forms of risedronate or its salts
#424Low dosage forms of risedronate or its salts
#425METHOD OF TREATING AND PREVENTING HYPERPARATHYROIDISM WITH ACTIVE VITAMIN D ANALOGS
#426Dosage forms of bisphosphonates
#427HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH
#428METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF BONE LOSS
#429TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH
#430PERCUTANEOUS PREPARATIONS
#431BIOMATERIAL
#432Phosphoinositide modulation for the treatment of neurodegenerative diseases
#433INHALANT FORMULATIONS COMPRISING A BISPHOSPHONATE AND A PYRAZOLONE DERIVATIVE AND METHODS FOR USING THE SAME
#434Methods of Using Phosphoantigen for the Treatment of Cancer
#435Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate
#436Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
#437Method of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
#438Solid oral dosage form containing an enhancer
#439Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
#440VĪ³9VĪ“2 T cell proliferation agent, method for producing activated VĪ³9VĪ“2 T cells, and uses thereof
#441COMBINATION COMPRISING N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-(1,3,4-OXADIAZOL-2-YL)PHENYL) PYRIDINE-3-SULPHONAMIDE AND AN LHRH ANALOGUE AND/OR A BISPHOSPHONATE
#442M-csf specific monoclonal antibody and uses thereof
#443Combinations comprising epothilones and pharmaceutical uses thereof
#444Solid dosage form of coated bisphosphonate particles
#445Combination therapy using a soluble hyaluronidase and a bisphosphonate
#446Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators
#447Use of thiophoshonoformic acid and nrtis to treat viral infections
#448Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
#449COMPOSITIONS AND METHODS FOR TREATING DIABETES
#450Use of clodronic acid for treatment podotrochlosis
#451Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
#452METHODS FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS
#453Adhesive preparation
#454Bisphosphonates for treating endometriosis
#455Bone targeted therapeutics and methods of making and using the same
#456Osteogenic and anti-adipogenic oxysterols
#457COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR
#458NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE
#459Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
#460Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
#461Use of dendrimers to stimulate cell growth
#462Effervescent compositions comprising phosphonates and methods related thereto
#463METHOD FOR TREATING AND PREVENTING HYPERPARATHYROIDISM
#464Compositions and methods for use for antibodies against sclerostin
#465Methods useful in the treatment of bone resorption diseases
#466Methods of promoting growth of muscle tissue using ALK7
#467TREATING NEOPLASMS
#468Bisphosphonate formulation
#469Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
#470PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID
#471Method of Improving Treatments in Rheumatic and Arthritic Diseases
#472TARGETED BONE MARROW PROTECTION AGENTS
#473Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
#474Prodrugs activated by RNA-dependent DNA-polymerases
#475Use of Alternating Amine and Non-Amine Bisphosphonate Combinations For Treating Osteoporosis
#476BONE TARGETING OF DEGRADABLE DRUG FILLED NANOPARTICLES
#477Low Dosage Forms Of Risedronate Or Its Salts
#478Low Dosage Forms Of Risedronate Or Its Salts
#479Liposome Compositions
#480Treatment and prevention of bone loss using resolvins
#481CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE
#482METHOD FOR THE TREATMENT OF BONE DISORDERS
#483RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE
#484Method of treatment using bisphosphonic acid
#485Methods of modulating metastasis and skeletal related events resulting from metastases
#486Use of bisphosphonates for the treatment of osteogenesis imperfecta
#487METHOD OF ADMINISTERING BISPHOSPHONATES
#488Tablets Comprising a High Load of Strontium
#489Risedronate compositions and their methods of use
#490USE OF BISPHOSPHONATES FOR PAIN TREATMENT
#491METHOD FOR PREVENTING OR REDUCING SECONDARY FRACTURES AFTER HIP FRACTURE
#492Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
#493Pharmaceutical Compositions Containing Biophosphonate for Improving Oral Absorption
#494Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
#495Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
#496DIPHOSPHONIC ACID PHARMACEUTICAL COMPOSITIONS
#497TRANSDERMAL DELIVER OF ACTIVE AGENTS
#498Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
#499Combinations comprising epothilones and pharmaceutical uses thereof
#500METHODS AND COMPOSITIONS FOR STIMULATING BONE GROWTH USING NITRIC OXIDE RELEASING BISPHOSPHONATE CONJUGATES (NO-BISPHOSPHONATE)
#501Treatment and Prevention of Heat Shock Protein-Associated Diseases and Conditions
#502Therapeutic Agent for Metastatic Cancer and Cancer Metastasis Inhibitor
#503Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
#504Use of Atp Analogues for Treatment of Cardiovascular Diseases
#505Solid oral dosage form containing an enhancer
#506Genetic modification of the lung as a portal for gene delivery
#507GDF-9/BMP-15 modulators for the treatment of bone disorders
#508TFIIS and GDOWN1 as targets for cancer therapy
#509Pharmaceutical Uses of Bisphosphonates
#510Compositions and methods for the treatment of tumors and tumor metastases
#511Method for administering ibandronate
#512P2x receptor inhibitor
#513Method of inhibiting restenosis using bisphosphonates
#514Method for the treatment of bone disorders
#515Method of administering bisphosphonates
#516Pharmaceutically active compounds and methods of use thereof
#517Inhibitor of cancer bone metastasis
#518Pharmaceutical formulations of bisphosphonates
#519Composition and method for the treatment of carcinoma
#520Pharmaceutical formulation with improved stability
#521Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
#522Novel uses of known drugs
#523Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
#524Cathepsin cysteine protease inhibitors
#525Methods of preserving ophthalmic solutions and preserved ophthalmic solutions
#526Methods of reducing the severity of mucositis
#527Film coated tablet for improved upper gastrointestinal tract safety
#528Transmucosal drug delivery system
#529Bisphosphonate formulation
#530Therapeutic liposomes
#531Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
#532Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
#533Therapy for Alzheimer's disease
#534Pharmaceutical products comprising bisphosphonates
#535Methods for treating arthritic conditions
#536PROPHYLACTIC AND THERAPEUTIC TREATMENT OF THE DUCTAL EPITHELIUM OF A MAMMARY GLAND FOR CANCER
#537Pharmaceutical compositions to treat diseases caused by mycobacterium
#538Combination comprising N-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate
#539Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
#540Prevention and treatment of influenza with glutamine antagonist agents
#541METHOD OF PREVENTION AND TREATMENT OF AGING, AGE-RELATED DISORDERS AND/OR AGE-RELATED MANIFESTATIONS INCLUDING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, CORONARY ARTERY DISEASE, OSTEOPOROSIS, ARTHRITIS, TYPE 2 DIABETES, DEMENTIA, ALZHEIMERS DISEASE AND CANCER
#542Agents and methods for enhancing bone formation
#543Method of modifying the release profile of sustained release compositions
#544Effervescent compositions comprising bisphosphonates and methods related thereto
#545Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
#546Controlled release dosage forms
#547Controlled released dosage forms
#548Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient
#549Disodium pamidronate formulation
#550Methods useful in the treatment of bone resorption diseases
#551Nanoparticulate bisphosphonate compositions
#552Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative
#553Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
#554Agent inducing increase in bone mass
#555Method of treatment using bisphosphonic acid
#556Bisphosphonates for the treatment of atherosclerosis and device comprising them
#557Enteric composition for the manufacture of soft capsule wall
#558Diphosphonate solutions
#559Diphosphonate solutions
#560Formulations of bisphosphonate drugs with improved bioavailability
#561Charged phospholipid compositions and methods for their use
#562Dosage forms of risedronate
#563Remedies for ischemic disease
#564Synbiotics
#565Methods of treating and preventing bone loss
#566Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
#567Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses
#568Methods and compositions for the treatment of diseases characterized by pathological calcification
#569Method for inhibiting bone resorption
#570Method of treating ischemia-reperfusion injury
#571Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
#572Pharmaceutical compositions for controlled release delivery of biologically active compounds
#573Effervescent bisphosphonate formulation
#574Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor through administration of a pyrophosphate analog
#575ALK7 and myostatin inhibitors and uses thereof
#576Controlled release alpha lipoic acid formulation with an inositol compound
#577Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection
#578Phosphonate-phosphate and diphosphonate apolipoprotein e modulators
#579Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent
#580Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions
#581Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
#582Therapy using a combination of raloxifene and alendronate
#583Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
#584Method for preventing or reducing secondary fractures after hip fracture
#585Method of adminstering bisphosphonates
#586Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog
#587Compositions and methods for inhibiting bone resorption
#588Dosage forms of bisphosphonates
#589Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
#590Pharmaceutically active compounds and methods of use thereof
#591Methods of treating skin with diphosphonate derivatives
#592Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
#593Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
#594Liquid injectable formulation of disodium pamidronate
#595Desensitization of compliment activation using monocyte/macrophage inhibitory compounds
#596Methods compositions and articles of manufacture for modulating bone growth
#597Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
#598Pharmaceutical composition for oral use with improved absorption
#599Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
#600Percutaneous preparations